Business Wire

nShift: Belgian Companies Must Act Fast to Meet Minimum Delivery Options Requirements

6.9.2024 12:15:00 EEST | Business Wire | Press release

Share

Belgium’s online retailers have just 16 days to comply with a new legal requirement to provide their customers with greater delivery choice. New legislation demands that from 21 September, webshops and ecommerce retailers in Belgium must provide at least two methods for the delivery of products to consumers. Retailers will be free to choose the delivery method but (at least) one of the options is encouraged to be eco-friendly.

It’s why nShift, the global leader in experience and delivery management (DMXM) is introducing a new and limited time offer designed to help retailers comply with the new law and offer a better customer experience. New customers in Belgium will receive 25% off a subscription to any of nShift’s solutions for six months.

Sean-Sherwin Smith, Product Director, Post Purchase at nShift said, “The new law marks a major shift in how online retailers will operate across Belgium. The new rule emphasizes sustainability and customer convenience. It marks a significant change in the regulatory landscape and means multi-carrier capability must be central to how retailers operate in the future.

"Sustainability is a core part of nShift’s offer. Our 1000+ carrier library features numerous sustainable last-mile solutions. Our Checkout functionality makes it easier to quickly badge and label more sustainable delivery options so shoppers can quickly find what they are looking for.”

Multi-carrier capability

Retailers will be able to respond to these changes more easily and efficiently if they work with a delivery management partner that offers multi-carrier capabilities. Beyond meeting the new legal requirement, working with a variety of carriers means retailers can offer real choice to shoppers, gain the agility to adapt to shifting consumer demand, and grow their business. Multi-carrier deliveries enable retailers to:

  • Offer a range of delivery options - shoppers expect to find the shipping solution they seek
  • Boost delivery capacity - making it easier to respond to increased demand
  • Improve delivery quality and efficiency – by gaining real data about the performance of each carrier
  • Grow beyond borders - shipping internationally requires relationships with carrier companies that serve the relevant territories
  • Build the brand and remarket to customers – by taking control of customer communications

Multi-carrier capability is at the heart of nShift’s DMXM suite of solutions. It provides enterprise-grade delivery management with a library of 1000+ ready-made carrier connections. nShift can connect retailers and consumers to over one million PUDO (pick up / drop off) locations. Retailers can automate the carrier-booking and label-printing process. This helps retailers send out more parcels, work with more carriers, and tightly control the delivery experience.

Sherwin-Smith concluded, “Businesses affected by the new law need to act fast but it’s also important they make the necessary adjustments in a scalable and sensible way. They must work with a partner that offers choice and convenience, particularly when it comes to eco-friendly carriers and emissions tracking capabilities.”

For more information on the offer or to find out how nShift could help your business with its multi-carrier offering, please visit our website, www.nshift.com.

About nShift

nShift’s delivery & experience management platform drives ecommerce success. Grow beyond limits with constant innovation and the world’s largest carrier network. Build customer loyalty with end-to-end tools that enhance experience. Unify data into usable insight that connects and optimizes processes. With nShift, make delivery the essential link between your brand and your customers.

nShift. Worry less. Ship smarter. www.nshift.com

Notes to editors

Under Article VI.45/2 of the Code of Economic Law, webshops will be required to offer at least two delivery methods, including one that is eco-friendly.

This offer is not available to existing customers and cannot be combined with any other discount or promotion. The offer is valid from 00:01 05 September 2024 until midnight on 31 December 2024.

Full subscription agreement will outline contractual terms, Customer will be granted optional termination 90 days from “Start Date”. A minimum of 14 days’ notice of termination must be given. This email does not represent contractual obligation. Promotion excludes existing “Track” service customers; customers with an existing signed “Track” subscription agreement. nShift AB standard terms and conditions apply. Promotional offer will run until 30th November 2023. nShift reserves the right to close promotional offer.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240906823045/en/

Contacts

James Ellerington:
James.Ellerington@fourteenforty.uk / (+44) 07725 534941

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye